Categories
Colon Cancer

Colon cancer screening guidelines updated: 45 is the new 50, medical task force says [Video]

An “alarming” rise in colorectal cancer cases among young people has led the United States Preventive Services Task Force to establish new guidelines.

Medical experts are now officially recommending that people of average risk start getting screened for colon cancer at age 45, rather than 50, which was the previous standard.

The announcement Tuesday morning finalizes prior draft guidance last fall, and aligns with the American Cancer Society’s stance. It indicates a solidifying push for awareness, and underscores the urgency of better, more widespread screening amongst age groups that may not know they’re at risk.

Insurance coverage is directly tied to the task force’s new recommendations, in fact, experts noted that companies will now be required to cover such screenings.

Now, millions of younger Americans can get checked for the condition at no out-of-pocket cost.

“The prognosis is so much better if you catch it at an earlier stage, for …

Watch/Read More
Categories
Colon Cancer

Molecular drivers and therapeutic targets for neuroendocrine transformation in lung cancer [Video]

Triparna Sen, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, talks on an investigation into molecular drivers and therapeutic targets for neuroendocrine transformation in lung cancer. EGFR-mutant adenocarcinoma transforms into small cell lung cancer (SCLC) as a mechanism of resistance to tyrosine kinase inhibitors (TKIs). A mutliomic analysis was conducted on combined histology tumors, whereby the lung adenocarcinoma and SCLC components were in the same spatial region. Microdissection of samples were performed and analyzed via various platforms, including Whole Exome Sequencing (WES), bulk RNA-sequencing, methylation analysis and immunohistochemistry. Via WES, p53 and RB1 loss were found in almost all combined histology tumors. Via bulk RNA-Seq, NOTCH inhibition and upregulation of several PCR2 complexes and DNA damage response genes were shown to be predictors of transformation. Additionally, AKT inhibition demonstrated to be an effective therapeutic target in a mutant mouse model. Notably, the addition of osimertinib to AKT inhibition performed better in mouse models than either agent alone. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.